Norwegian health authorities recommend screening regulary for women between the age of 25 and 69. The screening programme is reminder-based and relies on centralised registration and monitoring of all cervical cytology, HPV-tests, cervical histology, and treatment of CIN lesions and cancer. The Cancer Registry of Norway administers the programme in cooperation with the Directorate of Health . The organised programme was piloted regionally in 1992-1994 and implemented nationally in 1995. The programme is operated by regulation (decree) since 2002.
HPV-testing in conjunction with cytology, has been indicated since 2005 for triage of borderline and low-grade squamous intraepithelial lesions (ASC-US and LSIL) 6-12 months after the index screen.
Primary HPV screening has been implemented for 50% of the women between the age of 34 and 69 years in four counties (Rogaland, Hordaland, Sør- and Nord-Trøndelag) from 2015. Between 2019 and 2022 national roll-out of primary HPV screening will be conducted.
Representatives of professional groups involved in screening form an advisory board that monitors and offers advice on quality assurance functions, reminder routines, and modifications of guidelines or programme processes. A steering board at the Directorate of Health reviews the recommendations of the advisory board.